trending Market Intelligence /marketintelligence/en/news-insights/trending/fwm5ugahpppi_npaqwvkyg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Tesaro, Genentech team up to evaluate drug combo in bladder cancer

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Tesaro, Genentech team up to evaluate drug combo in bladder cancer

Tesaro Inc. and Genentech Inc. are partnering to evaluate the combination of the latter's immunotherapy Tecentriq and Tesaro's ovarian cancer drug Zejula in patients with advanced bladder cancer.

The arrangement includes testing the experimental combination in Morpheus, Roche Holding AG's cancer immunotherapy platform, to develop combinations of cancer immunotherapies more rapidly and efficiently.

The planned trial will be conducted by Genentech and is expected to begin in mid-2018.

Genentech is a unit of Roche.